Brought to you by 
Epizyme sells Royalty Pharma future royalties on Japanese sales of tazemetostat
29 May 2020
Executive Summary
Epizyme Inc. assigned Royalty Pharma the future royalty streams on Japanese sales of tazemetostat (an oral EZH2 inhibitor candidate for both solid tumors and hematological malignancies). In exchange, Epizyme could receive as much as $570mm in financing, with up to a $200mm equity investment from Royalty Pharma and up to $370mm in debt financing from Pharmakon Advisors, a Royalty Pharma affiliate. Epizyme has appointed a representative from Royalty Pharma to its board.
Deal Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Financing
- Nonconvertible Debt
- Royalty Sale
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Epizyme sells Royalty Pharma future royalties on Japanese sales of tazemetostat
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice